Ketorolac Dosing for a 12-Year-Old, 128 Pounds
For a 12-year-old child weighing 128 pounds (58 kg), administer ketorolac 0.5 mg/kg intravenously (approximately 30 mg as a single dose), not to exceed 30 mg maximum, with treatment duration limited to 48 hours maximum in the pediatric population.
Dosing Rationale
The FDA-approved ketorolac formulation is not approved for oral use in children under 17 years of age 1. The oral formulation is only indicated as continuation therapy following IV/IM dosing in adults 1. Therefore, this child should receive intravenous ketorolac only.
Weight-Based Calculation
- Patient weight: 128 pounds = 58 kg
- Standard pediatric IV dose: 0.5 mg/kg 2, 3, 4
- Calculated dose: 58 kg × 0.5 mg/kg = 29 mg
- Administer 30 mg IV (rounding to practical dosing)
Maximum Dose Considerations
Recent high-quality evidence demonstrates a ceiling effect at 15 mg in pediatric patients, with no additional analgesic benefit from higher doses 5, 6. However, the established pharmacokinetic data shows children have:
- 2-fold higher volume of distribution compared to adults 1
- Higher plasma clearance due to lower protein binding 1, 4
- Similar elimination half-life to adults (5-6 hours) 1
These pharmacokinetic differences support the higher weight-based dosing (0.5 mg/kg) in children versus the adult ceiling of 15-30 mg 4.
Dosing Schedule
- Single IV dose: 0.5 mg/kg (max 30 mg) 2, 3
- If repeat dosing needed: 0.5 mg/kg every 6 hours 2, 3
- Alternative continuous infusion: 0.17 mg/kg/hour 4
- Maximum daily dose: 90 mg 4
- Maximum treatment duration: 48 hours 4
Critical Safety Considerations
Contraindications to Screen For:
- Aspirin/NSAID-induced asthma 7
- Active bleeding or bleeding disorders 7
- Renal dysfunction (ketorolac associated with acute kidney injury, especially with preexisting renal impairment) 8
- Concomitant aspirin use (increases bleeding risk) 8
- Dehydration (ensure adequate hydration before administration)
Bleeding Risk
The 2024 meta-analysis of 11,729 pediatric patients showed doses of 0.9-1.0 mg/kg significantly increase primary operative bleeding (OR 4.07) and significant bleeding (OR 2.32), while 0.5 mg/kg did not increase bleeding risk 9. This strongly supports the 0.5 mg/kg dosing recommendation.
Renal Monitoring
- Monitor creatinine if treatment extends beyond single dose 8
- Ketorolac caused creatinine elevation in infants <6 months when used for 48 hours, though values remained within normal limits 8
- Use with extreme caution if any baseline renal impairment
Alternative Lower-Dose Strategy
Emerging evidence suggests 0.25-0.5 mg/kg with a 15 mg ceiling may provide equivalent analgesia with improved safety 5, 6, 10:
- A 2024 ED study of 599 pediatric patients showed no difference in pain reduction between 15 mg and >15 mg doses 5
- Another 2024 study in headache patients ≥60 kg showed 15 mg was non-inferior to 30 mg with mean pain score reduction of 5.1 vs 3.9 (p<0.001, favoring lower dose) 6
However, given the established pharmacokinetic data supporting higher weight-based dosing in children and the lack of prospective trials establishing 15 mg as adequate across all pediatric pain conditions, the standard 0.5 mg/kg dose (30 mg for this patient) remains the evidence-based recommendation 2, 4.
Clinical Pearls
- Administer IV push over 5 minutes to minimize adverse effects 11
- Assess pain at 30 and 60 minutes post-administration 11
- Consider multimodal analgesia: Ketorolac combined with acetaminophen provides superior pain control and opioid-sparing effects 8, 2
- Avoid in tonsillectomy patients due to increased bleeding risk at higher doses 9
- The oral formulation cannot be used as initial therapy in this age group 1